Literature DB >> 9223728

Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection.

Z Prohászka1, J Nemes, T Hidvégi, F D Tóth, K Kerekes, A Erdei, J Szabó, E Ujhelyi, N Thielens, M P Dierich, P Späth, B Ghebrehiwet, H Hampl, J Kiss, G Arlaud, G Füst.   

Abstract

OBJECTIVE: To study the mechanism of the complement-mediated antibody-dependent enhancement (C'-ADE) of HIV infection which may play a significant role in the progression of HIV-disease.
METHODS: In vitro complement activating and complement-mediated HIV-infection enhancing abilities of three human anti-gp41 monoclonal antibodies (MAb) were tested. C'-ADE was estimated using HIV-1IIIB and CR2 (CD21)-carrying MT-4 target cells. Normal human serum (NHS), purified C1q, C1q-deficient (C1qD) and C2-deficient (C2D) human sera were applied as complement sources.
RESULTS: All MAb mediated increased C1q binding to solid-phase gp41. All MAb had a marked dose-dependent and strictly complement-mediated HIV-infection enhancing effect. Mixtures of the MAb with purified C1q also significantly increased HIV-1 infection. C1qD serum had a markedly lower enhancing effect than NHS, which could be raised to normal level by addition of purified C1q. Pretreatment of the target cells with anti-CR2 antibodies only partially inhibited the enhancing effect of the MAb plus normal human serum.
CONCLUSION: These novel findings indicate that besides the well-known facilitation of entry of HIV-1 by the interaction between virus-bound C3 fragments and CR2 present on the target cells, fixation of C1q to intact virions also results in an enhanced productive HIV-1 infection in the MT-4 cell cultures.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223728     DOI: 10.1097/00002030-199708000-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  20 in total

1.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

Review 2.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 3.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

4.  Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment.

Authors:  V H Barbai; E Ujhelyi; J Szlávik; I Vietorisz; L Varga; E Fey; G Füst; D Bánhegyi
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

5.  Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.

Authors:  Dimitri Lavillette; Yoann Morice; Georgios Germanidis; Peggy Donot; Alexandre Soulier; Emanuil Pagkalos; Georgios Sakellariou; Liliane Intrator; Birke Bartosch; Jean-Michel Pawlotsky; François-Loïc Cosset
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.

Authors:  Zoltán Prohászka; Ferenc D Tóth; Dénes Bánhegyi; George Füst
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

7.  Human serum protein enhances HIV-1 replication and up-regulates the transcription factor AP-1.

Authors:  Maria F Perdomo; Waltteri Hosia; Alenka Jejcic; Garry L Corthals; Anders Vahlne
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-09       Impact factor: 11.205

8.  SERPING1 mRNA overexpression in monocytes from HIV+ patients.

Authors:  C Sanfilippo; D Cambria; A Longo; M Palumbo; R Avola; M Pinzone; G Nunnari; F Condorelli; G Musumeci; R Imbesi; P Castogiovanni; L Malaguarnera; Michelino Di Rosa
Journal:  Inflamm Res       Date:  2017-09-09       Impact factor: 4.575

9.  Antibody-dependent enhancement of Ebola virus infection.

Authors:  Ayato Takada; Heinz Feldmann; Thomas G Ksiazek; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Authors:  Suzanne Willey; Marlén M I Aasa-Chapman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Robin A Weiss; Stuart J D Neil
Journal:  Retrovirology       Date:  2011-03-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.